AleAnna (NASDAQ:ANNA) and Corbus Pharmaceuticals (NASDAQ:CRBP) Head to Head Review

Corbus Pharmaceuticals (NASDAQ:CRBP) and AleAnna (NASDAQ:ANNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Risk & Volatility

Corbus Pharmaceuticals has a beta of 2.78, indicating that its stock price is 178% more volatile than the S&P 500. Comparatively, AleAnna has a beta of -1.19, indicating that its stock price is 219% less volatile than the S&P 500.

Institutional & Insider Ownership

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of AleAnna shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 42.9% of AleAnna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Corbus Pharmaceuticals and AleAnna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-65.76%	-57.88%
AleAnna	-46.01%	-14.90%	-8.74%

Valuation and Earnings

This table compares Corbus Pharmaceuticals and AleAnna”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.98)	-1.70
AleAnna	$25.04 million	21.00	-$12.34 million	$0.04	197.25

AleAnna has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Corbus Pharmaceuticals and AleAnna, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	6	2	2.80
AleAnna	1	0	0	0	1.00

Corbus Pharmaceuticals presently has a consensus target price of $43.71, indicating a potential upside of 329.84%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than AleAnna.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.